Literature DB >> 3277594

Can potential hazard of Creutzfeldt-Jakob disease infectivity be reduced in the production of human growth hormone? Inactivation experiments with the 263K strain of scrapie. Rapid communication.

M Pocchiari1, G Macchi, S Peano, A Conz.   

Abstract

Scrapie infectivity is reduced 5-6 logs following filtration through 100,000 MW cut-off filter plus overnight treatment with 6 M urea. These steps, applied to purified human Growth Hormone (hGH), increase the margin of safety of hGH.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3277594     DOI： 10.1007/bf01321014

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  16 in total

1.  Further studies on scrapie.

Authors:  J T STAMP; J G BROTHERSTON; I ZLOTNIK; J M MACKAY; W SMITH
Journal:  J Comp Pathol       Date:  1959-07       Impact factor: 1.311

Review 2.  Prions: novel infectious pathogens.

Authors:  S B Prusiner
Journal:  Adv Virus Res       Date:  1984       Impact factor: 9.937

3.  Newer data on the inactivation of scrapie virus or Creutzfeldt-Jakob disease virus in brain tissue.

Authors:  P Brown; R G Rohwer; D C Gajdusek
Journal:  J Infect Dis       Date:  1986-06       Impact factor: 5.226

4.  Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy.

Authors:  P Brown; D C Gajdusek; C J Gibbs; D M Asher
Journal:  N Engl J Med       Date:  1985-09-19       Impact factor: 91.245

5.  Virus sterility for human growth hormone.

Authors:  P Brown
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

6.  Preparation of growth hormone free from contamination with unconventional slow viruses.

Authors:  D M Taylor; A G Dickinson; H Fraser; P A Robertson; P R Salacinski; P J Lowry
Journal:  Lancet       Date:  1985-08-03       Impact factor: 79.321

7.  Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery.

Authors:  C Bernoulli; J Siegfried; G Baumgartner; F Regli; T Rabinowicz; D C Gajdusek; C J Gibbs
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

8.  Course of experimental scrapie virus infection in the goat.

Authors:  W J Hadlow; C M Eklund; R C Kennedy; T A Jackson; H W Whitford; C C Boyle
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

9.  Large-scale preparation of highly purified pyrogen-free human growth hormone for clinical use.

Authors:  R L Jones; G Benker; P R Salacinski; T J Lloyd; P J Lowry
Journal:  J Endocrinol       Date:  1979-07       Impact factor: 4.286

10.  Characteristics of a short incubation model of scrapie in the golden hamster.

Authors:  R H Kimberlin; C Walker
Journal:  J Gen Virol       Date:  1977-02       Impact factor: 3.891
View more
  5 in total

1.  Physical properties of the Creutzfeldt-Jakob disease agent.

Authors:  T K Sklaviadis; L Manuelidis; E E Manuelidis
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

2.  Public health issues and clinical and neurological characteristics of the new variant of Creutzfeldt-Jakob disease and other human and animal transmissible spongiform encephalopathies: memorandum from two WHO meetings.

Authors: 
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

Review 3.  Experimental drug treatment of scrapie: a pathogenetic basis for rationale therapeutics.

Authors:  M Pocchiari; M Salvatore; A Ladogana; L Ingrosso; Y G Xi; M Cibati; C Masullo
Journal:  Eur J Epidemiol       Date:  1991-09       Impact factor: 8.082

Review 4.  Susceptibility of cell substrates to PrPSc infection and safety control measures related to biological and biotherapeutical products.

Authors:  Matthew LeBrun; Hongsheng Huang; Xuguang Li
Journal:  Prion       Date:  2008-01-13       Impact factor: 3.931

Review 5.  Prions and related neurological diseases.

Authors:  M Pocchiari
Journal:  Mol Aspects Med       Date:  1994
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.